CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Radiesse injectable implant and 2% lidocaine HCLdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02949921
NCT02949921N/ACompleted

Radiesse® Post Approval Safety Study - Radiological Evaluation of Implantation in the Hands

Merz North America, Inc.·interventional·Posted Oct 31, 2016·Updated Nov 29, 2023

In Brief

A clinical study evaluating Radiesse injectable implant and 2% lidocaine HCL for Volume Loss in the Dorsum of the Hand. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The objective of this study is to provide a preliminary assessment of the radiographic appearance of Radiesse material that has been injected into the dorsum of the hands.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 31, 2016
Enrollment StartDec 1, 2015
Primary CompletionJan 2, 2018
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.7 years ago

Interventions

Radiesse injectable implant and 2% lidocaine HCLdevice

Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.